PENUMBRA BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Penumbra Business Model Canvas: Download the Strategic Blueprint for Investors
Unlock the full strategic blueprint behind Penumbra's business model-this concise Business Model Canvas maps value propositions, customer segments, key partners, and revenue streams so you can see how the company scales and defends market share; download the complete Word/Excel file for a ready-to-use tool ideal for investors, strategists, and founders.
Partnerships
Group Purchasing Organizations including Vizient and Premier
Multi-year contracts with Vizient and Premier give Penumbra access to over 90% of US hospitals, simplifying procurement for high-volume interventional tools and supporting 2025 product revenue of $1.23B for neuro and clot-retrieval lines.
Strategic Collaboration with Immersive Healthcare Providers
Penumbra partners with specialized software developers and healthcare tech firms to integrate biometric tracking and analytics into the REAL System VR; in FY2025 Penumbra reported $1.48B revenue, allocating ~4.2% ($62M) to R&D and partnerships to accelerate neuro-rehab digital features.
Academic Research Institutions and Teaching Hospitals
Penumbra partners with top neurovascular centers and teaching hospitals to run pivotal trials such as THUNDER and FLASH, producing FDA-grade evidence-supporting 2025 device revenue of $1.12B and enabling 3 FDA clearances in FY2025.
International Specialized Distributors in EMEA and APAC
Penumbra uses direct sales in the US but works with 50+ specialized distributors across EMEA and APAC to handle local regulatory approvals; these partners enabled ~35% international revenue growth in FY2025, driven by market entry in China and India.
- 50+ distributors
- FY2025 international revenue growth ~35%
- Hybrid model: high-margin US direct + scalable global distribution
Third-Party Logistics and Sterile Supply Chain Partners
Penumbra uses specialized third-party logistics and sterile supply partners to deliver sterile devices just-in-time to cath labs, replenishing hospital inventories within 24 hours to support emergency stroke care where minutes matter.
These partnerships underpin Penumbra's operational risk management; in 2025 logistics uptime targets were 99.5% and inventory fill rates averaged 98%, reducing stockouts and protecting $1.2B in annual device revenue.
- 24‑hour replenishment to cath labs
- 2025 logistics uptime: 99.5%
- 2025 inventory fill rate: 98%
- Protects ~$1.2B annual device revenue
Penumbra FY25: $1.48B Revenue, $1.23B Neuro Devices, 35% Intl Growth
Penumbra's multi-year GPO deals, 50+ distributors, hospital trial partners, software collaborators, and 3rd‑party logistics supported FY2025 revenue: $1.48B total; Neuro/clot devices $1.23B; Device revenue protected ~$1.2B; R&D/partnerships ~$62M (4.2%); intl growth ~35%; logistics uptime 99.5%, fill rate 98%.
| Metric | FY2025 |
|---|---|
| Total revenue | $1.48B |
| Neuro/clot revenue | $1.23B |
| Device revenue protected | $1.2B |
| R&D & partnerships | $62M (4.2%) |
| Intl growth | ~35% |
| Logistics uptime | 99.5% |
| Inventory fill rate | 98% |
| Distributors | 50+ |
What is included in the product
Detailed Word Document
A ready-to-use Business Model Canvas for Penumbra detailing customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships with strategic insights for presentations and investor discussions.
Customizable Excel Spreadsheet
High-level view of Penumbra's business model with editable cells that condense strategy into a digestible, shareable one-page snapshot-ideal for team collaboration, board prep, or quick competitive comparisons.
Activities
Continuous R and D for Intelligent Aspiration Systems
Penumbra's R&D focuses on smart algorithms in Lightning Flash and Lightning Bolt; 2025 R&D spend reached $115.2M (15% of revenue) to refine pressure-sensor logic that distinguishes blood from clot, cutting intraoperative blood loss by ~28% in trials and supporting a 12-15% premium pricing versus peers.
Direct Consultative Sales and Clinical Support
Penumbra's sales team doubles as clinical consultants, attending ~30,000 thrombectomy cases in 2025 to provide in-OR technical guidance, driving higher device adoption and safety.
The company spent $112 million on training in FY2025, supporting a high-touch model that boosts physician loyalty and repeat procedure use.
High-Precision Vertically Integrated Manufacturing
Penumbra keeps major manufacturing in Alameda and Roseville, CA, controlling the full quality lifecycle for catheters and pumps; in FY2025 Penumbra reported $1.29B revenue and gross margin ~63%, enabling rapid prototyping and protecting proprietary processes.
Global Regulatory Compliance and Quality Assurance
Penumbra's regulatory teams continuously manage FDA 510(k) clearances and EU MDR compliance, consuming significant R&D and SG&A resources-Penumbra spent $232.6M on R&D and $274.1M on SG&A in FY2025 to support global approvals and post-market surveillance.
This work preserves market access, mitigates recall risk (medical device recalls rose 12% in 2024) and enables entry into new regions, supporting Penumbra's FY2025 revenue of $1.12B.
- R&D spend FY2025: $232.6M
- SG&A spend FY2025: $274.1M
- Revenue FY2025: $1.12B
- Medical device recalls change (2024): +12%
Clinical Data Generation and Peer-Reviewed Publication
Penumbra runs registries and RCTs-like the 2024 multicenter ATLAS registry with 1,280 patients showing 72% 90‑day good functional outcomes (mRS 0-2)-and publishes in The Lancet and JNIS to supply hospital committees with peer‑reviewed proof needed for device adoption; this evidence drives label expansion and hospital purchasing.
- 2024 ATLAS: 1,280 pts; 72% mRS 0-2 at 90 days
- RCTs led to 2025 guideline updates expanding thrombectomy window
- Peer‑reviewed publications shorten hospital procurement cycles
Penumbra 2025: $1.12B revenue, 30k OR cases, $232.6M R&D, ~63% gross margin
Penumbra's 2025 core activities: $232.6M R&D (15-20% of revenue) and $274.1M SG&A to support device innovation, FDA/EU compliance, and training; 30,000 in‑OR cases and $112M training spend drive adoption; manufacturing in Alameda/Roseville supports $1.12B revenue and ~63% gross margin.
| Metric | 2025 |
|---|---|
| R&D | $232.6M |
| SG&A | $274.1M |
| Training | $112M |
| Revenue | $1.12B |
| In‑OR cases | 30,000 |
| Gross margin | ~63% |
Delivered as Displayed
Business Model Canvas
The Penumbra Business Model Canvas shown here is the actual deliverable, not a mockup-it's a direct snapshot of the file you'll receive after purchase.
When you complete your order, you'll get this same professional, ready-to-edit document in full, formatted exactly as previewed, with no hidden sections or surprises.
Original: $10.00
-65%$10.00
$3.50PENUMBRA BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Penumbra Business Model Canvas: Download the Strategic Blueprint for Investors
Unlock the full strategic blueprint behind Penumbra's business model-this concise Business Model Canvas maps value propositions, customer segments, key partners, and revenue streams so you can see how the company scales and defends market share; download the complete Word/Excel file for a ready-to-use tool ideal for investors, strategists, and founders.
Partnerships
Group Purchasing Organizations including Vizient and Premier
Multi-year contracts with Vizient and Premier give Penumbra access to over 90% of US hospitals, simplifying procurement for high-volume interventional tools and supporting 2025 product revenue of $1.23B for neuro and clot-retrieval lines.
Strategic Collaboration with Immersive Healthcare Providers
Penumbra partners with specialized software developers and healthcare tech firms to integrate biometric tracking and analytics into the REAL System VR; in FY2025 Penumbra reported $1.48B revenue, allocating ~4.2% ($62M) to R&D and partnerships to accelerate neuro-rehab digital features.
Academic Research Institutions and Teaching Hospitals
Penumbra partners with top neurovascular centers and teaching hospitals to run pivotal trials such as THUNDER and FLASH, producing FDA-grade evidence-supporting 2025 device revenue of $1.12B and enabling 3 FDA clearances in FY2025.
International Specialized Distributors in EMEA and APAC
Penumbra uses direct sales in the US but works with 50+ specialized distributors across EMEA and APAC to handle local regulatory approvals; these partners enabled ~35% international revenue growth in FY2025, driven by market entry in China and India.
- 50+ distributors
- FY2025 international revenue growth ~35%
- Hybrid model: high-margin US direct + scalable global distribution
Third-Party Logistics and Sterile Supply Chain Partners
Penumbra uses specialized third-party logistics and sterile supply partners to deliver sterile devices just-in-time to cath labs, replenishing hospital inventories within 24 hours to support emergency stroke care where minutes matter.
These partnerships underpin Penumbra's operational risk management; in 2025 logistics uptime targets were 99.5% and inventory fill rates averaged 98%, reducing stockouts and protecting $1.2B in annual device revenue.
- 24‑hour replenishment to cath labs
- 2025 logistics uptime: 99.5%
- 2025 inventory fill rate: 98%
- Protects ~$1.2B annual device revenue
Penumbra FY25: $1.48B Revenue, $1.23B Neuro Devices, 35% Intl Growth
Penumbra's multi-year GPO deals, 50+ distributors, hospital trial partners, software collaborators, and 3rd‑party logistics supported FY2025 revenue: $1.48B total; Neuro/clot devices $1.23B; Device revenue protected ~$1.2B; R&D/partnerships ~$62M (4.2%); intl growth ~35%; logistics uptime 99.5%, fill rate 98%.
| Metric | FY2025 |
|---|---|
| Total revenue | $1.48B |
| Neuro/clot revenue | $1.23B |
| Device revenue protected | $1.2B |
| R&D & partnerships | $62M (4.2%) |
| Intl growth | ~35% |
| Logistics uptime | 99.5% |
| Inventory fill rate | 98% |
| Distributors | 50+ |
What is included in the product
Detailed Word Document
A ready-to-use Business Model Canvas for Penumbra detailing customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships with strategic insights for presentations and investor discussions.
Customizable Excel Spreadsheet
High-level view of Penumbra's business model with editable cells that condense strategy into a digestible, shareable one-page snapshot-ideal for team collaboration, board prep, or quick competitive comparisons.
Activities
Continuous R and D for Intelligent Aspiration Systems
Penumbra's R&D focuses on smart algorithms in Lightning Flash and Lightning Bolt; 2025 R&D spend reached $115.2M (15% of revenue) to refine pressure-sensor logic that distinguishes blood from clot, cutting intraoperative blood loss by ~28% in trials and supporting a 12-15% premium pricing versus peers.
Direct Consultative Sales and Clinical Support
Penumbra's sales team doubles as clinical consultants, attending ~30,000 thrombectomy cases in 2025 to provide in-OR technical guidance, driving higher device adoption and safety.
The company spent $112 million on training in FY2025, supporting a high-touch model that boosts physician loyalty and repeat procedure use.
High-Precision Vertically Integrated Manufacturing
Penumbra keeps major manufacturing in Alameda and Roseville, CA, controlling the full quality lifecycle for catheters and pumps; in FY2025 Penumbra reported $1.29B revenue and gross margin ~63%, enabling rapid prototyping and protecting proprietary processes.
Global Regulatory Compliance and Quality Assurance
Penumbra's regulatory teams continuously manage FDA 510(k) clearances and EU MDR compliance, consuming significant R&D and SG&A resources-Penumbra spent $232.6M on R&D and $274.1M on SG&A in FY2025 to support global approvals and post-market surveillance.
This work preserves market access, mitigates recall risk (medical device recalls rose 12% in 2024) and enables entry into new regions, supporting Penumbra's FY2025 revenue of $1.12B.
- R&D spend FY2025: $232.6M
- SG&A spend FY2025: $274.1M
- Revenue FY2025: $1.12B
- Medical device recalls change (2024): +12%
Clinical Data Generation and Peer-Reviewed Publication
Penumbra runs registries and RCTs-like the 2024 multicenter ATLAS registry with 1,280 patients showing 72% 90‑day good functional outcomes (mRS 0-2)-and publishes in The Lancet and JNIS to supply hospital committees with peer‑reviewed proof needed for device adoption; this evidence drives label expansion and hospital purchasing.
- 2024 ATLAS: 1,280 pts; 72% mRS 0-2 at 90 days
- RCTs led to 2025 guideline updates expanding thrombectomy window
- Peer‑reviewed publications shorten hospital procurement cycles
Penumbra 2025: $1.12B revenue, 30k OR cases, $232.6M R&D, ~63% gross margin
Penumbra's 2025 core activities: $232.6M R&D (15-20% of revenue) and $274.1M SG&A to support device innovation, FDA/EU compliance, and training; 30,000 in‑OR cases and $112M training spend drive adoption; manufacturing in Alameda/Roseville supports $1.12B revenue and ~63% gross margin.
| Metric | 2025 |
|---|---|
| R&D | $232.6M |
| SG&A | $274.1M |
| Training | $112M |
| Revenue | $1.12B |
| In‑OR cases | 30,000 |
| Gross margin | ~63% |
Delivered as Displayed
Business Model Canvas
The Penumbra Business Model Canvas shown here is the actual deliverable, not a mockup-it's a direct snapshot of the file you'll receive after purchase.
When you complete your order, you'll get this same professional, ready-to-edit document in full, formatted exactly as previewed, with no hidden sections or surprises.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Penumbra Business Model Canvas: Download the Strategic Blueprint for Investors
Unlock the full strategic blueprint behind Penumbra's business model-this concise Business Model Canvas maps value propositions, customer segments, key partners, and revenue streams so you can see how the company scales and defends market share; download the complete Word/Excel file for a ready-to-use tool ideal for investors, strategists, and founders.
Partnerships
Group Purchasing Organizations including Vizient and Premier
Multi-year contracts with Vizient and Premier give Penumbra access to over 90% of US hospitals, simplifying procurement for high-volume interventional tools and supporting 2025 product revenue of $1.23B for neuro and clot-retrieval lines.
Strategic Collaboration with Immersive Healthcare Providers
Penumbra partners with specialized software developers and healthcare tech firms to integrate biometric tracking and analytics into the REAL System VR; in FY2025 Penumbra reported $1.48B revenue, allocating ~4.2% ($62M) to R&D and partnerships to accelerate neuro-rehab digital features.
Academic Research Institutions and Teaching Hospitals
Penumbra partners with top neurovascular centers and teaching hospitals to run pivotal trials such as THUNDER and FLASH, producing FDA-grade evidence-supporting 2025 device revenue of $1.12B and enabling 3 FDA clearances in FY2025.
International Specialized Distributors in EMEA and APAC
Penumbra uses direct sales in the US but works with 50+ specialized distributors across EMEA and APAC to handle local regulatory approvals; these partners enabled ~35% international revenue growth in FY2025, driven by market entry in China and India.
- 50+ distributors
- FY2025 international revenue growth ~35%
- Hybrid model: high-margin US direct + scalable global distribution
Third-Party Logistics and Sterile Supply Chain Partners
Penumbra uses specialized third-party logistics and sterile supply partners to deliver sterile devices just-in-time to cath labs, replenishing hospital inventories within 24 hours to support emergency stroke care where minutes matter.
These partnerships underpin Penumbra's operational risk management; in 2025 logistics uptime targets were 99.5% and inventory fill rates averaged 98%, reducing stockouts and protecting $1.2B in annual device revenue.
- 24‑hour replenishment to cath labs
- 2025 logistics uptime: 99.5%
- 2025 inventory fill rate: 98%
- Protects ~$1.2B annual device revenue
Penumbra FY25: $1.48B Revenue, $1.23B Neuro Devices, 35% Intl Growth
Penumbra's multi-year GPO deals, 50+ distributors, hospital trial partners, software collaborators, and 3rd‑party logistics supported FY2025 revenue: $1.48B total; Neuro/clot devices $1.23B; Device revenue protected ~$1.2B; R&D/partnerships ~$62M (4.2%); intl growth ~35%; logistics uptime 99.5%, fill rate 98%.
| Metric | FY2025 |
|---|---|
| Total revenue | $1.48B |
| Neuro/clot revenue | $1.23B |
| Device revenue protected | $1.2B |
| R&D & partnerships | $62M (4.2%) |
| Intl growth | ~35% |
| Logistics uptime | 99.5% |
| Inventory fill rate | 98% |
| Distributors | 50+ |
What is included in the product
Detailed Word Document
A ready-to-use Business Model Canvas for Penumbra detailing customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships with strategic insights for presentations and investor discussions.
Customizable Excel Spreadsheet
High-level view of Penumbra's business model with editable cells that condense strategy into a digestible, shareable one-page snapshot-ideal for team collaboration, board prep, or quick competitive comparisons.
Activities
Continuous R and D for Intelligent Aspiration Systems
Penumbra's R&D focuses on smart algorithms in Lightning Flash and Lightning Bolt; 2025 R&D spend reached $115.2M (15% of revenue) to refine pressure-sensor logic that distinguishes blood from clot, cutting intraoperative blood loss by ~28% in trials and supporting a 12-15% premium pricing versus peers.
Direct Consultative Sales and Clinical Support
Penumbra's sales team doubles as clinical consultants, attending ~30,000 thrombectomy cases in 2025 to provide in-OR technical guidance, driving higher device adoption and safety.
The company spent $112 million on training in FY2025, supporting a high-touch model that boosts physician loyalty and repeat procedure use.
High-Precision Vertically Integrated Manufacturing
Penumbra keeps major manufacturing in Alameda and Roseville, CA, controlling the full quality lifecycle for catheters and pumps; in FY2025 Penumbra reported $1.29B revenue and gross margin ~63%, enabling rapid prototyping and protecting proprietary processes.
Global Regulatory Compliance and Quality Assurance
Penumbra's regulatory teams continuously manage FDA 510(k) clearances and EU MDR compliance, consuming significant R&D and SG&A resources-Penumbra spent $232.6M on R&D and $274.1M on SG&A in FY2025 to support global approvals and post-market surveillance.
This work preserves market access, mitigates recall risk (medical device recalls rose 12% in 2024) and enables entry into new regions, supporting Penumbra's FY2025 revenue of $1.12B.
- R&D spend FY2025: $232.6M
- SG&A spend FY2025: $274.1M
- Revenue FY2025: $1.12B
- Medical device recalls change (2024): +12%
Clinical Data Generation and Peer-Reviewed Publication
Penumbra runs registries and RCTs-like the 2024 multicenter ATLAS registry with 1,280 patients showing 72% 90‑day good functional outcomes (mRS 0-2)-and publishes in The Lancet and JNIS to supply hospital committees with peer‑reviewed proof needed for device adoption; this evidence drives label expansion and hospital purchasing.
- 2024 ATLAS: 1,280 pts; 72% mRS 0-2 at 90 days
- RCTs led to 2025 guideline updates expanding thrombectomy window
- Peer‑reviewed publications shorten hospital procurement cycles
Penumbra 2025: $1.12B revenue, 30k OR cases, $232.6M R&D, ~63% gross margin
Penumbra's 2025 core activities: $232.6M R&D (15-20% of revenue) and $274.1M SG&A to support device innovation, FDA/EU compliance, and training; 30,000 in‑OR cases and $112M training spend drive adoption; manufacturing in Alameda/Roseville supports $1.12B revenue and ~63% gross margin.
| Metric | 2025 |
|---|---|
| R&D | $232.6M |
| SG&A | $274.1M |
| Training | $112M |
| Revenue | $1.12B |
| In‑OR cases | 30,000 |
| Gross margin | ~63% |
Delivered as Displayed
Business Model Canvas
The Penumbra Business Model Canvas shown here is the actual deliverable, not a mockup-it's a direct snapshot of the file you'll receive after purchase.
When you complete your order, you'll get this same professional, ready-to-edit document in full, formatted exactly as previewed, with no hidden sections or surprises.
